Design of clinical trials in cystic fibrosis [5] (multiple letters)

Lancet

Volumn 361, Issue 9354, 2003, Pages 349-350

  Southern, Kevin W ^a   Smyth, Rosalind L ^a   Equi, A ^b   Balfour Lynn, I ^b   Bush, A ^b   Rosenthal, M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STANDARDIZATION; TIME; VALIDATION PROCESS;

EID: 0037464736     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12352-5     Document Type: Letter

References (4)

1. Equi A Balfour-Lynn I Bush A Rosenthal M Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial Lancet 360 2002 978 984
2. Senn S Cross-over trials in clinical research 1993 John Wiley and Sons Chichester
3. Altman DG Practical statistics for medical research 1997 Chapman and Hall London
4. Elbourne DR Altman DG Higgins JP Curtin F Worthington HV Vail A Meta-analyses involving cross-over trials: methodological issues Int J Epidemiol 31 2002 140 149